Efforts have been put in studying AKT inhibitors for the treatment of breast cancer 17-19; however, no AKT inhibitors have been approved for clinical application so far although the PI3Kα inhibitor Alpelisib in combination with Fulvestrant has been approved for ERα-positive and HER2-negative breast cancer patients with PIK3CA gene mutation 20. Here, ERBB2 is linked to breast cancer.